Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
FAIL · Does not pass the screen
26.84 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price26.84 USD at the 6 Nov 2026 close
Fair value68.76. Our model only; the analyst targets sit too far from the price to cross-check it.
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.30, read 2026-11-02
Ethical does not pass the values gate
Price26.84 USD
Fair value68.76Our model only; the analyst targets sit too far from the price to cross-check it.
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-26Read Markdown26.71+0.5% to today Distribution gives way to Markdown after an 11% slide in 2 weeks
2026-10-11Read Distribution29.94-10.4% to today ✓Markup gives way to Distribution
2026-10-02Read Markup28.99-7.4% to today Markdown gives way to Markup
2026-07-02Read Markdown28.75-6.6% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Viking Therapeutics, Inc. holds its Distribution at $26.84. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$26.84
Valuation
N/A trailing · -5.46 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.75
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.02%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
75.44%
Below 33%
Interest-bearing cash and securities are 75.4% of assets, above the one-third limit.
Fail
Receivables
23.17%
Below 49%
Money owed to the company is 23.2% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Viking Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 75% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when VKTX's ethical verdict changes
Today VKTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; the analyst targets sit too far from the price to cross-check it.
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 58% discount to our $68.76 fair value.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 61.0% discount to the base estimate.
Where our models see it going: fair-value estimate $68.76, with a range of $35.00 to $68.76, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
A clinical bet on unproven metabolic drugs
Picture a lab team chasing one thyroid hormone candidate through years of trials with no product on the market yet. Viking fits that picture exactly. Revenue sits at zero, margins at zero and return on equity at minus seventy percent, so the business remains a pure cash burner at this stage. Analyst price targets look ambitious but sit far ahead of any approved therapy or recurring income.
We pass for a clear reason. The ethical screen returns insufficient data because basic financial ratios are missing, and our opportunity rating is none. Without those numbers we cannot judge either the durability of any future moat or the real governance behind the pipeline.
Risk sits high. Clinical failure, dilution and regulatory setbacks are the normal path for firms at this point, and the negative forward earnings multiple simply reflects that the company has yet to turn a profit. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VKTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markdown$26.09-2.3%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93.
2026-10-28Markdown$26.71+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$26.71+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown · changed$26.71+0.0%Entry 14
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$26.71+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$26.71+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$26.71+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$26.71+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$26.71+4.9%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$25.47-14.9%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
